Activation of the mitogen‐activated protein kinase–extracellular signal‐regulated kinase pathway in childhood B‐cell acute lymphoblastic leukemia. Issue 10 (20th May 2022)

• Record Type: Journal Article
• Authors: Pillai, Pallavi M.; Mallory, Nicole; Pierro, Joanna; Saliba, Jason; Newman, Daniel; Hu, Jiyuan; Bhatla, Teena; Raetz, Elizabeth; Carroll, William L.; Evensen, Nikki A.
• Is Part Of: Pediatric blood & cancer. Volume 69:Issue 10(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-05-20
• Subjects: MAPK pathway -- pediatric acute lymphoblastic leukemia -- phosphoflow cytometry -- RAS; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29771
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: RAS mutations are frequently observed in childhood B‐cell acute lymphoblastic leukemia (B‐ALL) and previous studies have yielded conflicting results as to whether they are associated with a poor outcome. We and others have demonstrated that the mitogen‐activated protein kinase–extracellular signal‐regulated kinase (MAPK) pathway can be activated through epigenetic mechanisms in the absence of RAS pathway mutations. Herein, we examined whether MAPK activation, as determined by measuring phosphorylated extracellular signal‐regulated kinase (pERK) levels in 80 diagnostic patient samples using phosphoflow cytometry, could be used as a prognostic biomarker for pediatric B‐ALL. The mean fluorescence intensity of pERK (MFI) was measured at baseline and after exogenous stimulation with or without pretreatment with the mitogen‐activated protein kinase kinase (MEK) inhibitor trametinib. Activation levels (MFI stimulated/MFI baseline) ranged from 0.76 to 4.40 (median = 1.26), and inhibition indexes (MFI stimulated/MFI trametinib stimulated) ranged from 0.439 to 5.640 (median = 1.30), with no significant difference between patients with wildtype versus mutant RAS for either. Logistic regression demonstrated that neither MAPK activation levels nor RAS mutation status at diagnosis alone or in combination was prognostic of outcome. However, 35% of RAS wildtype samples showed MAPK inhibition indexes greater than the median, thus raising the possibility that therapeutic strategies to inhibit MAPK activation may not be restricted to patients whose blasts display Ras pathway defects.